What Baseimmune does

Baseimmune is a London-based biotechnology company founded in 2019, originating from Imperial College London, that uses an AI-driven computational protein design platform to engineer synthetic antigens for vaccines and immunotherapies. The platform integrates AI-driven antigen design algorithms with structural modelling and experimental screening to create bespoke antigens that target multiple biological pathways simultaneously, addressing complex chronic diseases where single-target therapies have historically failed. The company's pipeline includes universal vaccine candidates for African swine fever, coronavirus, and malaria, and, following a March 2026 strategic pivot, a fibrosis program with idiopathic pulmonary fibrosis (IPF) as the lead indication, where proof-of-concept efficacy readouts are expected in 2026 and 2027.

Baseimmune monetizes through pharmaceutical partnerships, licensing agreements, and co-development deals rather than direct product sales. Its commercial strategy is enterprise-oriented: the company partners with delivery-technology providers such as Touchlight (for DNA-based coronavirus vaccines) and is backed by strategic and financial investors including Hoxton Ventures, IQ Capital, MSD Global Health Innovation Fund, and Creator Fund, having raised approximately $17.1 million across three rounds (pre-seed in April 2021, seed in November 2021, and Series A in February 2024). The leadership team comprises co-founder and CSO Joshua Blight, US-based CEO Kevin Walton, and founder/CTO Phillip Kemlo, supported by a fibrosis-focused Scientific Advisory Board drawn from Mount Sinai, USC, Cedars-Sinai, and Karolinska Institutet.

Name

Baseimmune

Legal name

Baseimmune Ltd

Website

https://baseimmune.co.uk

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Baseimmune is a London-based biotech that uses an AI-driven computational protein design platform to engineer synthetic antigens for universal vaccines (COVID, malaria, African swine fever) and a fibrosis pipeline led by an idiopathic pulmonary fibrosis program, monetizing through pharmaceutical partnerships and licensing.

Ownership category

akta.pro rank

Product category

Biotechnology

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)

akta.pro secondary industries

Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB), Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC), Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA) (HLAMAKAH)

Keywords

• Computational vaccine design
• AI antigen engineering
• Synthetic immunotherapy
• Protein design platform
• Multi-pathway immunotherapy

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Therapeutic Development and Licensing: Baseimmune develops immunotherapies through its computational protein design platform and generates revenue through licensing deals, co-development partnerships, and eventual product commercialization. The company is building a pipeline in fibrosis with IPF as lead program.
2. Vaccine Development Partnerships: Collaborative development agreements with pharmaceutical partners to develop universal vaccines for diseases including COVID, malaria, and African Swine Fever using the company's AI-driven design platform.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Baseimmune develops next-generation vaccines and immunotherapies using a proprietary computational protein design platform that combines AI-driven antigen design, structural modelling, and experimental screening to create synthetic antigens. The company is advancing a fibrosis pipeline with lead program targeting Idiopathic Pulmonary Fibrosis (IPF) through multi-pathway immunotherapy, alongside vaccine development programs for African Swine Fever, coronavirus, and malaria.

Product overview

Baseimmune develops next-generation immunotherapies using its proprietary computational protein design platform. The platform creates bespoke antigens by integrating multi-pathway antigen design, structural modelling, and experimental screening to address complex, chronic disease biology. The company's current portfolio includes a fibrosis pipeline focused on Idiopathic Pulmonary Fibrosis (IPF) and vaccine development programs targeting African swine fever, coronavirus, and malaria. The technology enables the creation of synthetic antigens that can be used across different vaccine technologies and adapt to emerging variants.

Differentiator

Problem solved

Functional benefit

Products and services

• Fibrosis Pipeline (IPF Program) Multi-pathway immunotherapy programs targeting fibrosis, initially focused on Idiopathic Pulmonary Fibrosis (IPF), using computational protein design to target multiple pro-fibrotic pathways simultaneously. Intended for pharmaceutical partners and ultimately patients with progressive fibrotic disease.
• Vaccine Development Programs (ASF, Coronavirus, Malaria) Universal vaccine candidates for African swine fever, coronavirus, and malaria developed using the company's AI-driven vaccine design platform to create synthetic antigens that adapt to emerging variants. Developed for pharmaceutical and animal health partners.
• Computational Protein Design Platform A proprietary antigen-design platform integrating computational protein design, structural modelling, and experimental screening to create therapeutics engineered for complex, chronic disease biology. Licensed and leveraged through partnerships.

Quantifiable outcome

• Proof-of-concept efficacy readouts expected in 2026 and 2027 for IPF program

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Partnerships

One partnership is on record.

• TouchlightcoreStrategic or Co-development PartnerPartnership to develop a universal coronavirus vaccine leveraging Touchlight's DNA technology combined with Baseimmune's AI-driven antigen design platform for creating synthetic antigens adaptable to emerging variants.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• CureVac: mRNA-based vaccine and immunotherapy company with a proprietary technology platform for infectious disease and oncology antigens. Directly comparable to Baseimmune as a platform-play biotech monetising a versatile antigen-design engine via partnerships and licensing.
• Vaxart: Clinical-stage vaccine company developing oral recombinant vaccines across infectious disease targets. Comparable as a small-cap platform biotech with multiple infectious-disease programmes and a licensing/partnership-oriented business model.
• SpyBiotech: Vaccine platform company using a proprietary protein-based antigen display technology for infectious disease targets. Comparable as a UK/European preclinical-stage platform biotech with licensing-oriented economics and a versatile antigen-display engine.
• Osivax: French clinical-stage biotech developing universal vaccines (notably universal influenza) using a self-assembling nanoparticle platform. Directly comparable to Baseimmune on the universal-vaccine narrative and partnership-driven economics.
• Centivax: Computational immunology company developing universal vaccines and antibody therapeutics using AI-driven antigen/antibody design. Closely comparable to Baseimmune on technology stack, pipeline (universal influenza, infectious disease) and stage.

Emerging players

• Icosavax: VLP (virus-like particle)-based vaccine platform company targeting infectious diseases including RSV and hMPV. Comparable as a small-cap platform vaccine biotech using computationally designed antigens, though at a more advanced clinical stage.
• Antiverse: UK-based biotech using AI/ML to design antibody therapeutics. Adjacent peer — comparable to Baseimmune on AI-driven computational protein design for biologics and on early-stage UK biotech stage, though focused on antibodies rather than vaccines.
• Pliant Therapeutics: Clinical-stage biotech developing integrin-based therapies for idiopathic pulmonary fibrosis and other fibrotic diseases. Comparable to Baseimmune specifically on the IPF lead programme and the broader fibrosis therapeutic opportunity.

Broad incumbents

• Moderna: mRNA platform company with established vaccine pipeline across COVID, influenza, RSV and other infectious diseases. Comparable as a platform-leverage vaccine business, with much larger manufacturing, regulatory and commercial infrastructure than Baseimmune.
• BioNTech: Global leader in mRNA-based vaccines and immunotherapies with multi-disease pipeline spanning infectious disease and oncology. Overlaps with Baseimmune on AI-driven antigen design, immunotherapy pipeline, and pharma-licensing business model, though at vastly greater scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/baseimmune
• LinkedInlinkedin.com/company/baseimmune
• Instagraminstagram.com/baseimmune/?hl=en

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Baseimmune